Pacifica Partners’s CRISPR Therapeutics CRSP Stock Holding History

Pacifica Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.1K	Buy	200 +170	+567%	+$9.17K	﹤0.01%	289
2026 Q2	$1.8K	Hold	30	–	–	﹤0.01%	398
2026 Q1	$1.43K	Hold	30	–	–	﹤0.01%	424
2025 Q4	$1.61K	Hold	30	–	–	﹤0.01%	407
2025 Q3	$1.98K	Hold	30	–	–	﹤0.01%	462
2025 Q2	$1.42K	Hold	30	–	–	﹤0.01%	489
2025 Q1	$979	Hold	30	–	–	﹤0.01%	483
2024 Q4	$1.24K	Hold	30	–	–	﹤0.01%	448
2024 Q3	$1.41K	Hold	30	–	–	﹤0.01%	467
2024 Q2	$1.62K	Hold	30	–	–	﹤0.01%	483
2024 Q1	$2.13K	Hold	30	–	–	﹤0.01%	459
2023 Q4	$2.12K	Hold	30	–	–	﹤0.01%	485
2023 Q3	$1.29K	Hold	30	–	–	﹤0.01%	491
2023 Q2	$1.7K	Hold	30	–	–	﹤0.01%	435
2023 Q1	$1.36K	Hold	30	–	–	﹤0.01%	454
2022 Q4	$1.23K	Hold	30	–	–	﹤0.01%	437
2022 Q3	$2K	Hold	30	–	–	﹤0.01%	422
2022 Q2	$2K	Hold	30	–	–	﹤0.01%	437
2022 Q1	$2K	Hold	30	–	–	﹤0.01%	433
2021 Q4	$2K	Hold	30	–	–	﹤0.01%	430
2021 Q3	$3K	Hold	30	–	–	﹤0.01%	400
2021 Q2	$5K	Buy	+30	New	+$3.65K	﹤0.01%	351
2020 Q2	–	Sell	-50	Closed	-$2K	–	379
2020 Q1	$2K	Hold	50	–	–	﹤0.01%	322
2019 Q4	$3K	Buy	+50	New	+$2.73K	﹤0.01%	307

Other funds holding CRSP

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Slow Capital Greenbrae, California $890M AUM 40.96% 1-Year Est. Return

NTV Asset Management Charleston, West Virginia $1.08B AUM 23.94% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

Canal Insurance Company Greenville, South Carolina $426M AUM 30.47% 1-Year Est. Return

Bouvel Investment Partners Phoenixville, Pennsylvania $433M AUM 51.2% 1-Year Est. Return

Pacifica Partners's CRSP Position: Q3 2026 in Review

Pacifica Partners increased its CRISPR Therapeutics (CRSP) stake by 567% in Q3 2026, buying an estimated $9.17K and bringing the position to 200 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #289.

Pacifica Partners first reported a position in CRSP in Q4 2019 and has held it in 24 quarters since. 88 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

Pacifica Partners held 200 shares of CRISPR Therapeutics worth $11.1K as of Q3 2026.
Pacifica Partners bought 170 CRISPR Therapeutics shares in Q3 2026, an estimated $9.17K.
CRISPR Therapeutics made up ﹤0.01% of Pacifica Partners's portfolio in Q3 2026, its #289 holding.
Pacifica Partners first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 24 quarters since.
88 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Pacifica Partners's 13F filing for Q3 2026, filed 9 Oct 2026.